Literature DB >> 11070175

IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development.

J M Townsend1, G P Fallon, J D Matthews, P Smith, E H Jolin, N A McKenzie.   

Abstract

Interleukin-9 is a cytokine produced by Th2 cells and is a candidate gene for asthma and atopy. We have generated IL-9-deficient mice to delineate the specific roles of IL-9 in Th2 responses. Using a pulmonary granuloma model, we have demonstrated a distinct requirement for IL-9 in the rapid and robust generation of pulmonary goblet cell hyperplasia and mastocytosis in response to lung challenge. In contrast, eosinophilia and granuloma formation were not affected. IL-9 was not required for T cell development or differentiation, the generation of naive or antigen-driven antibody responses, or the expulsion of the intestinal parasitic nematode Nippostrongylus brasiliensis. Thus, deletion of IL-9 manifests as a highly defined phenotype in Th2 responses modulating mucus production and mast cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070175     DOI: 10.1016/s1074-7613(00)00056-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  119 in total

1.  IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling.

Authors:  Daniel Traum; Patricia Timothee; Jonathan Silver; Stefan Rose-John; Matthias Ernst; David F LaRosa
Journal:  J Leukoc Biol       Date:  2011-12-02       Impact factor: 4.962

Review 2.  Targeting the Jak/STAT pathway for immunosuppression.

Authors:  J J O'shea
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Overexpression of Smad2 drives house dust mite-mediated airway remodeling and airway hyperresponsiveness via activin and IL-25.

Authors:  Lisa G Gregory; Sara A Mathie; Simone A Walker; Sophie Pegorier; Carla P Jones; Clare M Lloyd
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

Review 4.  The future of asthma therapy: integrating clinical and experimental studies.

Authors:  David B Corry; Farrah Kheradmand
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

6.  Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.

Authors:  Xiuhua Yao; Qingfei Kong; Xiaoli Xie; Jinghua Wang; Na Li; Yumei Liu; Bo Sun; Ying Li; Guangyou Wang; Wenjin Li; Siying Qu; Haijun Zhao; Dandan Wang; Xijun Liu; Yao Zhang; Lili Mu; Hulun Li
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 7.  IL-9 and Th9 cells in health and diseases-From tolerance to immunopathology.

Authors:  Junhui Li; Shuqiu Chen; Xiang Xiao; Yong Zhao; Wenjun Ding; Xian C Li
Journal:  Cytokine Growth Factor Rev       Date:  2017-07-17       Impact factor: 7.638

8.  IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.

Authors:  Timothy B Oriss; Mahesh Raundhal; Christina Morse; Rachael E Huff; Sudipta Das; Rachel Hannum; Marc C Gauthier; Kathryn L Scholl; Krishnendu Chakraborty; Seyed M Nouraie; Sally E Wenzel; Prabir Ray; Anuradha Ray
Journal:  JCI Insight       Date:  2017-05-18

Review 9.  Th9 and allergic disease.

Authors:  Pejman Soroosh; Taylor A Doherty
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

10.  Leptin Enhances TH2 and ILC2 Responses in Allergic Airway Disease.

Authors:  Handong Zheng; Xing Zhang; Eliseo F Castillo; Yan Luo; Meilian Liu; Xuexian O Yang
Journal:  J Biol Chem       Date:  2016-08-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.